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Gender disparities in scientiﬁc publications have been identiﬁed in oncological research. Oral research presentations at major
conferences enhance visibility of presenters. The share of women presenting at such podia is unknown. We aim to identify
gender-based differences in contributions to presentations at two major oncological conferences. Abstracts presented at
plenary sessions of the American Society of Clinical Oncology (ASCO) Annual Meetings and European Society for Medical
Oncology (ESMO) Congresses were collected. Trend analyses were used to analyze female contribution over time. The
association between presenter’s sex, study outcome (positive/negative) and journals’ impact factors (IFs) of subsequently
published papers was assessed using Chi-square and Mann–Whitney U tests. Of 166 consecutive abstracts presented at ASCO
in 2011–2018 (n = 34) and ESMO in 2008–2018 (n = 132), 21% had female presenters, all originating from Northern America
(n = 17) or Europe (n = 18). The distribution of presenter’s sex was similar over time (p = 0.70). Of 2,425 contributing authors
to these presented abstracts, 28% were women. The proportion of female abstract authors increased over time (p < 0.05) and
was higher in abstracts with female (34%) compared to male presenters (26%; p < 0.01). Presenter’s sex was not associated
with study outcome (p = 0.82). Median journals’ IFs were lower in papers with a female ﬁrst author (p < 0.05). In conclusion,
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there is a clear gender disparity in research presentations at two major oncological conferences, with 28% of authors and 21%
of presenters of these studies being female. Lack of visibility of female presenters could impair acknowledgement for their
research, opportunities in their academic career and even hamper heterogeneity in research.
What’s new?
Presenting one’s research at a conference is a great way to get your name and ideas heard within the professional community.
In this study, the authors investigated how often women served as presenters at plenary sessions of ASCO Annual Meetings
and ESMO Congresses. Looking through 166 abstracts over a period of 8 years, they found that 21% had female presenters,
while 28% of study authors were female. Lack of visibility for female researchers at conferences can slow their career progress,
and greater representation should be encouraged.
Introduction
Gender inequalities in science and medicine are increasingly
brought to the fore. Despite an expanding number of women
entering the ﬁeld of medicine, female physicians are still at disad-
vantage in obtaining jobs, less rewarded thanmen and underrepre-
sented in leadership positions.1–5 In medical research, gender
differences are even more pronounced: women are less likely to
hold ﬁrst-author positions on top publications, receive requested
grants, be invited as a peer reviewer, or become a full professor.1,4–7
Gender discrepancies in authorships of scientiﬁc publica-
tions have been identiﬁed in many disciplines all over the
world, including oncology.2,8–12 However, results of a clinical
research project are often ﬁrst brought to life through a pre-
sentation at an international conference. Such a presentation
gives the scientiﬁc study an actual identity through visibility
of the researcher. Presentations at major international confer-
ences are not only important for discussion of the outcomes
of a study, they also provide the presenter the opportunity for
recognition for as a principal investigator, and increase the
chance of climbing the academic career ladder.
Female underrepresentation in presenting studies and invitation
to speak at conferences has been identiﬁed in other disciplines.13–18
The exact share of women presenting at major oncological confer-
ences is not clear. In our study, we aimed to identify potential
gender-based differences in contributions to presentations at two
major international oncological conferences: the American Society
of Clinical Oncology (ASCO)AnnualMeetings and European Soci-
ety forMedical Oncology (ESMO)Congresses.
Methods
Data collection
We aimed to collect consecutive abstracts of all plenary ses-
sions of ASCO Annual Meetings and presidential sessions of
ESMO Congresses between 2000 and 2018. The abstracts
presented at these sessions are assumed to have the highest
impact on oncological research and practice. Speciﬁc data on
ASCO abstracts were available from 2011 and on ESMO
abstracts from 2008.
Data on ASCO abstracts, including sexes of the presenters,
were provided by ASCO Center for Research and Analytics for
all abstracts presented at the plenary sessions since 2011. All
consecutive ESMO abstracts presented at the presidential ses-
sions since 2008 were identiﬁed from the ESMO website (www.
esmo.org) or the website of the conference. Data extracted from
the abstracts included information on presenters, names and
order of authors, country of origin, study subject and results.
Sexes of presenters and authors were interpreted based on their
ﬁrst names or, if inconclusive, based on available online infor-
mation including photos and electronic portfolio of the speciﬁc
author. Study results were deﬁned as positive and negative if
they met or did not meet the primary endpoints, respectively,
and neither negative nor positive if results were not clear yet,
or if both positive and negative results were found.
From all abstracts, the subsequently published papers were
identiﬁed and corresponding impact factors (IFs) of the journals
in which they were published (obtained from InCites Journal
Citation Reports) were collected. One-year IFs of the year in
which the article was published were used, or of the previous year
in case IFs were not yet known. Any changes in authorships
compared to the presented abstract were identiﬁed.
Ethical approval to perform our study was not considered
to be necessary.
Statistical analysis
Descriptive statistics were used to display the distribution of
presenter’s and abstract author’s sex. Chi-square or Fisher’s
exact tests where appropriate were used to compare the sex
distribution in abstract presenters and authors per year. The
association between presenter’s or last author’s sex and distri-
bution of author’s sex, study outcome and IFs were analyzed
using Chi-square and Mann–Whitney U tests, respectively. A
trend in contribution of both sexes in presenters and abstract
authors over time was tested using the Cochran-Armitage
trend test; p-values lower than 0.05 were regarded as statisti-
cally signiﬁcant. Statistical analyses were performed using SAS
software (version 9.4, SAS institute, Cary, NC).
2 From presentation to paper: Gender disparities in oncological research
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The data that support the ﬁndings of our study are available
from the corresponding author upon reasonable request.
Results
Presenters
Data of 166 consecutive abstracts presented at plenary sessions
of ASCO Annual Meetings from 2011 and at ESMO Congresses
from 2008 were collected. Included abstracts of the plenary ses-
sions of ASCO Annual Meetings between 2011 and 2018
(n = 34) and of the presidential sessions of ESMO conferences
between 2008 and 2018 (n = 132) are shown in Tables 1 and 2,
respectively. References of all of these abstracts and subsequently
published papers can be found in the Supplementary Material.
Of all 166 abstracts, 35 (21%) were presented by a woman.
Although the proportion of female presenters has decreased
since 2015–2016 (Fig. 1), the distribution of female and male
contribution to presenters was not different over the years
(p = 0.699), neither was a trend observed in contribution of
both sexes over time (p = 0.350).
The majority of the presenters originated from Europe
(n = 90, 54%), followed by Northern America (n = 65, 39%),
Asia (n = 9, 5%) and Oceania (n = 2, 1%). All female pre-
senters came from Northern America (n = 17) or Europe
(n = 18). The share of women of all Northern American and
European presenters was 26 and 20%, respectively. Per coun-
try, 17 of 62 (27%) American, 5 of 29 (17%) British, 1 of
6 (17%) Belgian, 2 of 17 (12%) French, 6 of 13 (46%) Dutch,
2 of 4 (50%) Swiss, 1 of 5 (20%) Italian presenters and the
only Austrian presenter were female.
Almost a quarter of the studies presented by a female
researcher (n = 35) concerned breast cancer (n = 8, 23%), lung
cancer (n = 3, 9%), followed by ovarian cancer, colorectal cancer
and multiple types of cancer (all: n = 4, 11%). Other subjects are
shown in Tables 1 and 2. Overall, 26% of the presentations about
breast cancer, 44% about ovarian cancer, 29% about colorectal
cancer and 17% about lung cancer were presented by a woman.
Study outcomes were most often positive (n = 119, 71%),
while 33 (20%) had negative outcomes and 14 (8%) neither
positive nor negative (N/P), or nonapplicable (N/A). Out-
comes were positive, negative and N/P or N/A in 71, 23 and
6% of the 35 studies presented by a female researcher, and
72, 19 and 9% of 131 abstracts with male presenters, respec-
tively. The outcomes of presented abstracts did not differ
between male and female presenters (p = 0.746). Presenter’s
sex was not associated with study outcome (p = 0.815).
Abstract authors
Figure 1 shows the overall proportion of female presenters and
abstract authors. Of all authors of the presented abstracts
(n = 2,425), 679 (28%) were female, 1,728 (71%) were male and
sex was unknown in 19 (1%) authors. The distribution of sex of
abstract authors differed statistically signiﬁcantly over the years
(p = 0.046), and a positive trend was observed in contribution of
female authors over time (p = 0.007). The number of female
authors was higher in abstracts with a female presenter (34%)
compared to abstracts with a male presenter (26%; p = 0.001).
Overall, contribution of women to last abstract authorship
was 20% (n = 33). Last abstracts’ authors were female in 9/35
(26%) of the studies presented by a woman and in 23/131
(18%) of studies presented by a male researcher (p = 0.277).
Sex of the last abstract author was not associated with
study outcomes (p = 0.433).
Subsequently published papers
The majority of the 166 presented abstracts were subsequently
published in an international journal (n = 156, 94%). In
56 (36%) of these 156 papers, either the ﬁrst or last author
was a woman. Female researchers were involved as ﬁrst
author in 29 (19%) and last author in 32 (21%) articles.
A total of 30/35 (86%) abstracts presented by a woman were
published as article, which was statistically signiﬁcantly less than
the 126/131 (96%) abstracts with a male presenter that resulted in
a paper (p = 0.021). In 4/30 (13%) articles, the female presenter
of the abstract was not involved as ﬁrst, second or last author,
and the ﬁrst authors of these papers were all males (A-2017-1,
E-2011-4, E-2013-8 and E-2015-10; Tables 1 and 2). In 3/126
(2%) published papers with a male abstract presenter, the pre-
senter was not ﬁrst, second or last author of the article, and all the
ﬁrst authors were other males (E-2010-2, E-2011-1, E-2017-1;
Table 2).
Median IF of journals of papers with a female ﬁrst author
was 20.3 (interquartile range [IQR], 8.4, 53.4), which was lower
than of papers with a male ﬁrst author (median IF 35.4 [IQR,
20.5, 59.1]; p = 0.046). Sex of the presenter, last abstract author,
or last author of the manuscript were not associated with IF of
journals of subsequently published papers (p = 0.101, p = 0.864
and p = 0.922, respectively).
Figure 1. Proportion of female presenters and abstract authors over
time at plenary sessions of American Society of Clinical
Oncology (ASCO) Annual Meetings and European Society for Medical
Oncology (ESMO) Congresses. Results of 2008–2010 is based on
ESMO abstracts solely. Abstract authors with unknown sex (n = 19)
are not displayed.
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Figure 2 shows the sex distribution of abstract presenters in both
ASCO and ESMO conferences. The distribution of sex of pre-
senters did not differ between ASCO and ESMO (p = 0.756), but
the proportion of female authors in ASCO abstracts (32%) was
signiﬁcantly higher compared to those of ESMO (27%; p = 0.048).
When analyzing the meetings separately, we found a statisti-
cally signiﬁcant positive trend in female contribution observed
in ESMO abstract authors (p = 0.014), which was not found in
ASCO abstract authors (p = 0.544). This trend over time in
female contribution was not identiﬁed in ASCO and ESMO
presenters (p = 0.350 and p = 0.656).
Discussion
Although gender differences have been acknowledged in medical
research,1,2,5,6,8,9 this is the ﬁrst study to describe the gender gap in
contribution to research presentations at the two largest oncologi-
cal conferences in the world. Of all oncological studies presented
at the main sessions of the past 8 ASCO Annual Meetings and
12 ESMO Congresses, the number of female presenters did not
reach a quarter. In subsequently published papers, the share of
female ﬁrst and last authors was even smaller. The gender gap
appears to be more prominent in oncological research than in
clinical practice, because nearly half of the hematology–oncology
fellowship trainees in the United States,19,20 more than half of
medical oncologists in several European countries21 and 37% of
ASCO and 41% of ESMO members are female.22 Moreover, we
found an association between sex of ﬁrst author of subsequently
published manuscripts and the journal’s IF. Although IFs of these
journals were all relatively high, which is not surprising given that
these studies were presented at the most important sessions of the
conferences, this corresponds with ﬁndings about the underrepre-
sentation of female authors in high-impact journals.23,24
The lack of women presenting at oncological conferences is in
line with the trend of gender differences in other research areas,
where males numerically outweigh females, despite an increase in
women entering scientiﬁc careers.1,2,9,25,26 The number of publica-
tions by male researchers remains signiﬁcantly higher than those
by females, as is also seen in authorships of oncological publica-
tions.10,12 In our study, we found an overall female contribution
to abstract authorships of 27–31%, with an increase of female
contribution as abstract authors over time. However, this rise was
not observed among female presenters at both conferences.
Although it was not a statistically signiﬁcant trend, the proportion
of female presenters since 2015 appears to be shrinking rather
than increasing and is therefore worrisome (Fig. 1).
Over the span of their academic career, publication pro-
ductivity of women increases at a later stage of their career
compared to men.4,27 While the publication productivity of
female researchers exceeded those of male researchers toward
Figure 2. Distribution of sex in both American Society of Clinical Oncology (ASCO) and European Society for Medical Oncology (ESMO)
abstract presenters and authors.
Dijksterhuis et al. 9












the end of their careers, that is, after 27 years of service, most
leadership appointments occurred before the 20th year of ser-
vice.4 Because productivity is an important factor in the selec-
tion of leaders, this could be one of the causes for the
underrepresentation of women in leading positions. As not
only the content of the abstract, but also past productivity and
leadership positions may inﬂuence the selection of presenters
for the most important sessions of ASCO and ESMO confer-
ences, this could partly explain the underrepresentation of
female presenters in these sessions as well.
Interpretation of data on gender disparities, including our
data, may be hindered by a Simpson’s paradox, as described
earlier.28,29 This paradox implies that an apparent association
can actually be a result of a third dependent factor. For exam-
ple, a ﬁnding that female researchers received requested grants
less often than men was biased because women applied more
often for grants in more competitive research ﬁelds.28 More
speciﬁcally, our ﬁndings could be the result of self-selection, in
case that less women chose to submit an abstract to ASCO and
ESMO or indicated they wanted to give a poster presentation
rather than an oral presentation. In other scientiﬁc ﬁelds, gen-
der differences in presentations at a congress have been identi-
ﬁed as a result of self-selection.14,17,30 For example, in biology
women were asked less often as an invited speaker, even when
adjusted for career stage, but also declined invitations more
often than men.17 Similarly, at an anthropology conference,
women appeared to ask for oral presentations less frequently
than men, resulting in signiﬁcantly more poster and less oral
presentations than male reseachers.30 At an conference on evo-
lutionary biology, women presented for relatively shorter dura-
tion compared to men despite a ﬁfty-ﬁfty attendance, mainly
because men requested longer presentations more often.14
Unfortunately, we did not have information about the number
of submitted abstracts to ASCO and ESMO or whether the per-
sons who submitted the abstracts requested a presentation or a
poster. However, the ﬁndings in other ﬁelds highlight the possi-
bility of self-selection as a cause for the gender differences that
we found and emphasize the need for women to increase their
assertiveness in order to narrow the gender gap.
Gender, in contrast to sex, is a social construct of characteris-
tics as norms and roles of and between women and men, instead
of a “biological given” that is beyond our control.31,32 To open up
avenues for change, possible consequences of gender and its
behavior-based cause must be underlined.33 This starts with rec-
ognizing the gender gap34 and efforts to change perceptions of
inequality associated with gender, for example, on competence32,35
and meritocracy.24,27,35 Possible solutions beside acknowledge-
ment of these biases that could bridge the gap in (oncological)
research and level the playing ﬁeld for both sexes may include
encouragement of self-promotion in female researchers, and
implementation of guidelines that concern gender equality.33 For
example, this could start with involving more women in the orga-
nizing committees of conferences, because this has been positively
associated with female representation at conferences.13,30 Second,
the abstract assessment process could be changed by appraising
the abstracts without information on the presenter’s or authors’
sexes or names. Moreover, female presenters could inspire and
encourage female young researchers to follow their example.
Finally, because all the female presenters came from the USA or
Europe in our study, there should be greater awareness of the gen-
der gap among researchers originating from other parts of the
world.
Not only do gender gaps potentially disadvantage women,
they could also impair patients outcomes and science.1 In onco-
logical research, for example, several sex-based differences in the
treatment and outcomes of cancer patients have been explored
and revealed important issues in, for example, drug responses
and toxicity.36–38 The presence of a female author in a study has
been positively associated with the likelihood of the exploration
and analysis of these sex-based differences.39,40 Diversity in sex
of researchers could therefore also contribute to a more diverse
perception of science, possibly contributing to favorable out-
comes for patients in the end, especially in the light of recent
ﬁndings in sex-based differences in oncology.36
Our study has some limitations. We only included abstracts
presented at the most important sessions of two main oncologi-
cal conferences in the world, therefore we do not know the gen-
der balance in abstracts presented in other sessions or at other
conferences. Moreover, a considerable part of the abstracts
presented in 2018 were not yet published, which could have
resulted in a bias. Lastly, we did not have data on the sex distri-
bution of attendees at the conferences, or the proportion of
females that participate in oncological research worldwide to
compare this to the share of female presenters and abstract
authors.
In conclusion, the share of female presenters at the main
sessions of ASCO Annual Meetings and ESMO Congresses is
only 21%, and 28% in authorships of these presented abstracts.
Greater visibility of women at these large oncological confer-
ences should be encouraged to allow acknowledgement for
their research and opportunities for their academic career, as
well as positively drive heterogeneity in research through diver-
sity in sex of researches.
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